-
Host factors are the major determinants of the outcomes of C. meningosepticum infections. Lin and colleagues describe 9 adults (40-82 years of age) and 2 children (0.5 and 1.5 years of age) seen at 2 hospitals in Taiwan from 2001 to 2002 with bacteremia due to Chrysobacterium meningosepticum. Six of the infections were community acquired.
-
Caspofungin and flucytosine were the active antifungals against C. glabrata, while fluconazole was least active. Isolates with high level resistance to fluconazole demonstrated reduced susceptibility to voriconazole.
-
Nitazoxanide (Alinia) is a broad spectrum antiparasitic agent, previously approved for use as an oral suspension for the treatment of cryptosporidiosis and giardiasis in children. It has now received FDA approval as a 500 tablet for the treatment of giardiasis in adolescents and adults.
-
The High Cost of MRSA; Treatment of Latent TB: A High Priority; The APRICOT HCV/HIV Co-infection Study.
-
Viagra: Maximum Capacity at High-Altitudes?; FDA Actions.
-
Five days of oral treatment with azithromycin appeared to be at least as effective as a similar duration of treatment of treatment with ceftriaxone in children in Cairo with typhoid fever.
-
Sources of funding for pharmaceutical research has come under scrutiny in the last decade as academic and government sources of funding have become increasingly scarce and the pharmaceutical industry has become the main source of research dollars. But the issue of objectivity has been raised, and some have even suggested that negative studies, that is studies that show a drug in an unfavorable light, may never be published. The American Medical Association has recently tackled this issue and has asked the department of Health and Human Services to establish a public registry of all clinical trials in United States.
-
-
End-stage renal disease is a devastating condition that, according to the United States Renal Data System, plagued approximately 406,000 individuals in the United States in 2001 and is projected to increase to a prevalence of approximately 725,000 by 2010. Furthermore, it is a major public health issue, given the overall poor outcomes and high costs for this chronic condition.
-
